Overall Patient Characteristics
No. of patients | 21 |
Median age (yr) | 36 |
Sex (male/female) | 10/11 |
Diagnosis | |
AML | 5 |
ALL | 4 |
CML | 8 |
NHL | 3 |
SAA | 1 |
Conditioning regimen | |
CY/fTBI | 18 |
CY/VP16/fTBI | 3 |
GVHD prophylaxis | |
CSA/MTX | 17 |
CSA | 3 |
CSA/Pred | 1 |
BM donors | |
Serologic and LBT match | 18 |
Serologic and LBT mismatch | 3 |
Related/unrelated | 12/9 |
Sex mismatch | 13 |
Female donor to male recipient | 7 |
Median donor age (yr) | 38 |
Range | 20-62 |
No. of patients | 21 |
Median age (yr) | 36 |
Sex (male/female) | 10/11 |
Diagnosis | |
AML | 5 |
ALL | 4 |
CML | 8 |
NHL | 3 |
SAA | 1 |
Conditioning regimen | |
CY/fTBI | 18 |
CY/VP16/fTBI | 3 |
GVHD prophylaxis | |
CSA/MTX | 17 |
CSA | 3 |
CSA/Pred | 1 |
BM donors | |
Serologic and LBT match | 18 |
Serologic and LBT mismatch | 3 |
Related/unrelated | 12/9 |
Sex mismatch | 13 |
Female donor to male recipient | 7 |
Median donor age (yr) | 38 |
Range | 20-62 |
Abbreviations: AML, acute myeloid leukemia; ALL, acute lymphoblastic leukemia; CML, chronic myeloid leukemia; NHL, non-Hodgkin’s lymphoma; SAA, severe aplastic anemia; CY, cyclophosphamide; fTBI, fractionated total body irradiation; VP16, etoposide; CSA, cyclosporine A; MTX, methotrexate; Pred, methylprednisone; BM, bone marrow; LBT, ligation based typing of class II.